Racura Oncology Ltd banner

Prices of ASX stocks are not being updated. The latest RAC price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.

Intrinsic Value

The intrinsic value of Racura Oncology Ltd (RAC) under the Base Case is 2.67 AUD per share. Compared with the last price of 1.6 AUD on Oct 14, the stock appears Undervalued by 40% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

RAC Intrinsic Value
AU$2.67
Undervaluation 40%
Intrinsic Value
Price AU$1.6
Alert me when RAC is below its intrinsic value
Today AU$1.33 · 16.6% below the current price

RAC is cheaper than usual. This is its cheapest valuation in the past 5 years.

Alternatives to RAC

Fundamental Analysis

What Racura Oncology Does

Biotechnology Health Care

Race Oncology is an Australian biotechnology company that is trying to turn an old cancer drug, bisantrene, into a modern treatment. Its main work is research, lab testing, and clinical development of drug candidates for cancers such as acute myeloid leukemia and other hard-to-treat blood cancers. The company is not a mass-market drug maker; it is a development-stage biotech that is building evidence for its own medicine candidates and related intellectual property.

Headquarters
Australia AU
IPO date
Jul 13, 2016
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue RAC Research

Decided on Racura Oncology? Get an email when RAC reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one RAC stock?

The intrinsic value for Racura Oncology Ltd (RAC) under the Base Case is 2.67 AUD.

Is RAC stock undervalued or overvalued?

Compared with the last price of 1.6 AUD on Oct 14, the stock appears Undervalued by 40% .

How reliable are our estimates? See how past valuations played out
Back to Top